

# What are vasodilators?

- dilate blood vessels
  - Which vessels? – arteries, arterioles, venules and veins
  - How? – smooth muscle relaxation (direct/indirect)

## Why are they used?

- control blood pressure / blood flow
  - systemic / local (e.g. pulmonary, coronary, peripheral)
- ↓ the work of the heart (thus O<sub>2</sub> need)
  - heart failure / angina


- Vasodilators are used
  - to **antagonize increased vascular tone**
    - systemically or
    - locally
  - thus improve the efficacy of circulation under pathological conditions

## Sources of mediators controlling vascular smooth muscle tone

- secreted by **autonomic (sympathetic) nerves**
  - e.g. NAdr+, ATP+
- secreted by **endothelium**
  - e.g. endothelin+, prostacyclin ( $\text{PGI}_2$ )-, NO-
- **circulating hormones**
  - e.g. angiotensin+
- **other**
  - e.g. thromboxane ( $\text{TXA}_2$ )+, 5-HT+/-, natriuretic peptides-

## Excitation - contraction coupling in smooth muscle

eg. NAdr / angiotensin




- *ic. Ca is central*
- *but depol. and EC Ca is not absolute req.*


myosin phosphatase

vascular smooth muscle tension → diameter → blood pressure / flow

# Control of smooth muscle contraction and relaxation



## Role of endothelium in controlling vascular smooth muscle



some are tonically active: e.g. NAdr, NO, endothelin

# Endothelium derived mediators controlling vascular smooth muscle tension

- prostanoids
  - relax.: PGI<sub>2</sub>, PGE<sub>2</sub>
  - constr.: PGG<sub>2</sub>, PGH<sub>2</sub>
- nitric oxide
- peptides
  - relax.: CNP, adrenomedulin
  - constr.: **angiotensin II**, endothelin
- endothelium derived hyperpolarizing factor(s)
  - NO and PG independent vasodilation
  - identity ?

# Classification of vasodilators according to their mechanism of action

- *directly acting vasodilators*
  - calcium channel blockers – e.g. nifedipine
  - $K_{ATP}$  channel activators – e.g. minoxidil
  - drugs that increase cytoplasmic cyclic nucleotide concentrations
    - cyclase activators – e.g. nitrates,  $\beta_2$  agonists
    - PDE inhibitors – e.g. methylxantines, sildenafil
- *indirectly acting vasodilators*
  - drugs that interfere with the sympathetic nervous system
    - e.g.  $\alpha_1$  blockers
  - **RAS blockers** (aliskiren, captopril, losartan ...)
  - drugs that stimulate endothelial NO release – e.g. ACh, BK
  - drugs that block the endothelin system
    - bosentan, ambrisentan - used in pulmonary hypertension
- *other (unknown) mechanism of action*
  - hydralazine/dihydralazine, ethanol, propofol



# Directly acting vasodilators

- *calcium channel blockers* (L-type voltage dependent)
  - dihydropyridines - e.g. **nifedipine**
  - verapamil
  - diltiazem
- *K<sub>ATP</sub> channel activators*
  - **minoxidil**, diazoxide, nicorandil, levosimendan
- *cAMP/ cGMP level increasing drugs*
  - increased adenylyl cyclase activity
    - prostacyclin (PGI<sub>2</sub> / epoprostenol),  $\beta_2$  agonists, fenoldopam
  - increased guanylyl cyclase activity
    - **organic nitrates** (nitroglycerine, nitroprusside), NO, natriuretic peptides
  - phosphodiesterase inhibitors
    - **sildenafil** + others – erectile dysfunction
    - papaverin, theophylline, milrinone, inamrinone – not used as vasodilators

# Classification according to clinical use

- *hypertension*
  - calcium channel blockers - both outpatient and emergency
  - oral vasodilators: hydralazine and minoxidil - long-term outpatient therapy of severe hypertension
  - parenteral vasodilators: nitroprusside, diazoxide and fenoldopam - hypertensive emergencies
- *angina pectoris*
  - organic nitrates - for immediate relief
  - calcium channel blockers - especially for prophylaxis
- *heart failure (mainly acute severe form)*
  - several may improve symptoms (nitroprusside, phentolamine, nitrates)
  - hydralazine + isosorbide dinitrate
  - RAS blockers

# Ca<sup>2+</sup> channel blockers

- „use dependent” blockade
- heart > vascular: verapamil > diltiazem > nifedipine
  - no reflex tachycardia with verapamil
- arteriolar dilation
  - decreased blood pressure
  - coronaries – variant (Prinzmetal) angina
  - nimodipine – cerebral vessels – subarachnoid hemorrhage
- other smooth muscles
  - not significant – e.g. verapamil – constipation
- adverse effects
  - ankle edema
  - bradycardia, negative inotropy (verapamil)

# K<sup>+</sup> channel activators

- hyperpolarization – voltage dependent Ca<sup>2+</sup> channel ↓
- **minoxidil**
  - arteriolar, long duration, oral, severe hypertension, in combination
  - hirsutism (see Rogaine solution)
- **diazoxide**
  - iv., arteriolar dilator, long duration of action (4-12 hours)
  - now rarely used (and only for short periods)
  - tox: hypotension, inhibits insulin release – used in insulinoma
- **nicorandil**
  - NO donor too
  - arteriolar and venous effects
  - angina, currently approved for use in Europe and Japan
- **levosimendan**
  - see heart failure – Ca sensitizers
  - in acute heart failure in Europe, noninferiority against dobutamine

# Cyclase activators

- cGMP
  - nitrates – e.g. nitroglycerin, Na-nitroprusside
  - NO
  - nesiritide – BNP
- cAMP
  - fenoldopam / dopamine
  - $\beta_2$  agonists – not used as vasodilators / see asthma
  - prostacyclin (PGI<sub>2</sub> / epoprostenol)

# Nitrates / nitrites

- NO release
  - enzyme reaction: organic nitrates (e.g. nitroglycerine)
    - mitochondrial aldehyde dehydrogenase
  - “**direct release**” (e.g. Na-nitroprusside / molsidomine)
- **nitroglycerine** (glyceryl trinitrate)
  - acute angina – **sublingual** (peak ~ 4 min,  $t_{1/2}$  ~ 1-3 min)
    - amyl nitrite is obsolete for angina (short duration / unpleasant odor)
  - preferentially **venodilation** + epicardial coronaries + atherosclerotic stenosis + collateral vessels (no “coronary steal”)
  - inhibition of thrombocyte aggregation
  - long term administration deleterious ? (e.g. Nakamura et al. 1999)
- isosorbid dinitrate / **isosorbid-5-mononitrate** (oral F  $\approx$  100%)
- Na-nitroprusside
  - i.v. infusion, light sensitive, cyanide release
  - arterial effects  $\approx$  venous effects

# Nitrates / nitrites

- **tolerance**

- mechanism ?

- neurohumoral activation, SH depletion, free radicals, inactivation of mitochondrial aldehyde reductase ...

- to avoid/decrease: **intermittent dosing**

- **adverse effects**

- orthostatic hypotension

- tachycardia

- throbbing headache

- ↑ intracranial pressure (in case of overdose)

# Inhaled NO gas

- selective dilation of pulmonary vasculature
  - because rapid reaction of NO by hemoglobin
- ↓ pulmonary pressure, ↑ oxygenation
- FDA: newborns with persistent **pulmonary hypertension**
- questions – long term outcome???
  - ARDS
  - primary pulmonary hypertension
  - pulmonary embolism
  - lung transplantation



# Nesiritide

- synthetic BNP (B-type natriuretic peptide)
- effects
  - $\uparrow$ cGMP  $\rightarrow$  smooth muscle relax.
  - diuresis
- clinical use
  - iv. infusion
  - **acute heart failure**
- toxicity
  - excessive hypotension
  - renal damage ? / mortality ?

# Fenoldopam

- selective D<sub>1</sub> receptor agonist (cAMP ↑)
  - vasodilation
    - afferent and efferent arterioles in kidney
    - mesenteric arteries
  - natriuresis
- clinical use
  - short term iv. infusion in severe hypertension
- toxicity
  - due to vasodilation: tachycardia, headache, flushing
  - glaucoma

# Prostacyclin ( $\text{PGI}_2$ , epoprostenol)

- effects
  - cAMP  $\uparrow$
  - potent vasodilator
  - inhibitor of platelet aggregation
- use
  - iv. infusion ( $t_{1/2} \approx 2\text{-}3 \text{ min}$ )
    - analogs with longer half life
      - iloprost ( $t_{1/2} \approx 30 \text{ min}$ ) – inhaled / iv.
      - treprostinil ( $t_{1/2} \approx 4 \text{ h}$ ) – sc. / iv.
  - pulmonary hypertension
- toxicity
  - headache, flushing, hypotension
  - diarrhea

# Vasodilators in pulmonary hypertension


- endothelin receptor antagonists
  - bosentan, ambrisentan
  - oral / in mild cases
- prostanoid analogs
  - iloprost (inhal.), treprostinil (sc), beraprost
  - parenteral / in severe cases
- epoprostenol
  - long term iv. infusion
- NO inhalation
  - in newborn babies
- sildenafil
- Ca channel blockers

# PDE inhibitors

- theophylline
  - used in asthma / not only PDE inhibitor (adenosine antag.)
- papaverin
  - Ca channel block too
  - GI smooth muscle relaxation
- milrinone, inamrinone
  - PDE3 inhibitors, see positive inotropic drugs
  - ↑ contractility and vasodilation
- cilostazol
  - PDE3 inhibitor
  - used in intermittent claudication
- sildenafil
  - PDE5 inhibitor
  - used in erectile dysfunction / pulmonary hypertension

# Interaction of nitrates with PDE5 inhibitors

- risk factors for erectile dysfunction  $\approx$  coronary artery disease
- PDE5 inhibitors: sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra)
- profound cGMP  $\uparrow \rightarrow$  severely reduced BP



# Hydralazine / dihydralazine

- unknown mechanism of action
  - NO release ? (not K channels)
  - selective for arterioles
- orally administered
- clinical use
  - hypertension
    - hypertensive crisis during pregnancy – short term only
  - heart failure
    - in combination with nitrates (esp. African American)
- toxicity
  - headache, flushing, reflex tachycardia → angina
  - reversible lupus like syndrome
    - primarily in “slow acetylators”